Search: WFRF:(Houssiau Frederic)
> (2020-2024) >
From sequential to ...
-
Parodis, Ioannis,1981-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
(author)
From sequential to combination and personalised therapy in lupus nephritis : moving towards a paradigm shift?
- Article/chapterEnglish2022
Publisher, publication year, extent ...
-
2021-09-14
-
HighWire Press,2022
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-94436
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-94436URI
-
https://doi.org/10.1136/annrheumdis-2021-221270DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:148192551URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding agencies:Professor Nanna Svartz Foundation 2019-00290Ulla and Roland Gustafsson Foundation 2019-12Fondation Saint-LucFonds de la Recherche Scientifique - FNRS
-
The current treatment paradigm in lupus nephritis consists of an initial phase aimed at inducing remission and a subsequent remission maintenance phase. With this so-called sequential treatment approach, complete renal response is achieved in a disappointing proportion of 20-30% of the patients within 6-12 months, and 5-20% develop end-stage kidney disease within 10 years. Treat-to-target approaches are detained owing to uncertainty as to whether the target should be determined based on clinical, histopathological, or immunopathological features. Until reliable non-invasive biomarkers exist, tissue-based evaluation remains the gold standard, necessitating repeat kidney biopsies for treatment evaluation and therapeutic decision-making. In this viewpoint, we discuss the pros and cons of voclosporin and belimumab as add-on agents to standard therapy, the first drugs to be licenced for lupus nephritis after recent successful randomised phase III clinical trials. We also discuss the prospect of obinutuzumab and anifrolumab, also on top of standard immunosuppression, currently tested in phase III trials after initial auspicious signals. Undoubtably, the treatment landscape in lupus nephritis is changing, with combination treatment regimens challenging the sequential concept. Meanwhile, the enrichment of the treatment armamentarium shifts the need from lack of therapies to the challenge of how to select the right treatment for the right patient. This has to be addressed in biomarker surveys along with tissue-level mapping of inflammatory phenotypes, which will ultimately lead to person-centred therapeutic approaches. After many years of trial failures, we may now anticipate a heartening future for patients with lupus nephritis.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Houssiau, Frederic A.Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium; Rheumatology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium
(author)
-
Örebro universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Related titles
-
In:Annals of the Rheumatic Diseases: HighWire Press81:1, s. 15-190003-49671468-2060
Internet link
Find in a library
To the university's database